Mesoblast limited Company Profile (NASDAQ:MESO)

About Mesoblast limited (NASDAQ:MESO)

Mesoblast limited logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MESO
  • CUSIP: N/A
  • Web: www.mesoblast.com
Capitalization:
  • Market Cap: $656.69 million
  • Outstanding Shares: 76,094,000
Average Prices:
  • 50 Day Moving Avg: $10.42
  • 200 Day Moving Avg: $7.24
  • 52 Week Range: $3.50 - $12.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.51
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $31.97 million
  • Price / Sales: 20.54
  • Book Value: $6.71 per share
  • Price / Book: 1.29
Profitability:
  • EBIDTA: ($62,720,000.00)
  • Net Margins: -30.38%
  • Return on Equity: 5.87%
  • Return on Assets: 4.05%
Debt:
  • Current Ratio: 2.26%
  • Quick Ratio: 2.26%
Misc:
  • Average Volume: 40,560 shs.
  • Beta: 2.89
  • Short Ratio: 11.79
 

Frequently Asked Questions for Mesoblast limited (NASDAQ:MESO)

What is Mesoblast limited's stock symbol?

Mesoblast limited trades on the NASDAQ under the ticker symbol "MESO."

Where is Mesoblast limited's stock going? Where will Mesoblast limited's stock price be in 2017?

3 equities research analysts have issued 12-month target prices for Mesoblast limited's shares. Their forecasts range from $5.00 to $14.00. On average, they expect Mesoblast limited's share price to reach $9.17 in the next year. View Analyst Ratings for Mesoblast limited.

What are analysts saying about Mesoblast limited stock?

Here are some recent quotes from research analysts about Mesoblast limited stock:

  • 1. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (5/23/2017)
  • 2. Maxim Group analysts commented, "Summary Mesoblast is currently enrolling patients in its phase III pivotal trial for congestive heart failure. The goal is to prove that Revascor, Mesoblast’s allogeneic stem cell therapy, can demonstrate a therapeutic benefit in these patients." (3/31/2017)

Who are some of Mesoblast limited's key competitors?

When did Mesoblast limited IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Who owns Mesoblast limited stock?

Mesoblast limited's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (0.32%), Princeton Capital Management Inc. (0.20%), Osborn Williams & Donohoe LLC (0.03%) and Morgan Stanley (0.03%). View Institutional Ownership Trends for Mesoblast limited.

Who bought Mesoblast limited stock? Who is buying Mesoblast limited stock?

Mesoblast limited's stock was bought by a variety of institutional investors in the last quarter, including Princeton Capital Management Inc. and Morgan Stanley. View Insider Buying and Selling for Mesoblast limited.

How do I buy Mesoblast limited stock?

Shares of Mesoblast limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mesoblast limited stock cost?

One share of Mesoblast limited stock can currently be purchased for approximately $8.63.

Analyst Ratings

Consensus Ratings for Mesoblast limited (NASDAQ:MESO) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $9.17 (6.22% upside)

Analysts' Ratings History for Mesoblast limited (NASDAQ:MESO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/11/2017Maxim GroupReiterated RatingBuy$14.00LowView Rating Details
4/3/2017ScotiabankReiterated RatingHold$8.50LowView Rating Details
6/14/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$10.00 -> $5.00N/AView Rating Details
3/7/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$9.00 -> $10.00N/AView Rating Details
2/25/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
11/24/2015Ladenburg Thalmann Financial ServicesReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Mesoblast limited (NASDAQ:MESO)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Mesoblast limited (NASDAQ:MESO)
Current Year EPS Consensus Estimate: $-0.71 EPS
Next Year EPS Consensus Estimate: $-0.75 EPS

Dividends

Dividend History for Mesoblast limited (NASDAQ:MESO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast limited (NASDAQ:MESO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Mesoblast limited (NASDAQ:MESO)
Latest Headlines for Mesoblast limited (NASDAQ:MESO)
Source:
DateHeadline
reuters.com logoUPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs
www.reuters.com - May 25 at 4:33 AM
globenewswire.com logoMesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017 - GlobeNewswire (press release)
globenewswire.com - May 24 at 11:33 PM
fool.com logoIs the Mesoblast limited share price good value? - Motley Fool Australia
www.fool.com.au - May 24 at 11:33 PM
finance.yahoo.com logoMesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017
finance.yahoo.com - May 24 at 6:33 PM
americanbankingnews.com logoMesoblast limited (MESO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 19 at 12:08 AM
finance.yahoo.com logoETFs with exposure to Mesoblast Ltd. : May 9, 2017
finance.yahoo.com - May 9 at 6:12 PM
americanbankingnews.com logoMesoblast limited (MESO) Given Daily Media Impact Rating of 0.44
www.americanbankingnews.com - May 3 at 12:20 AM
americanbankingnews.com logoMesoblast limited (MESO) Getting Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 7:42 PM
fool.com logoWhy these 3 shares just made new 52-week highs
www.fool.com.au - April 28 at 12:05 AM
americanbankingnews.com logoMesoblast limited (MESO) Receives Daily Media Sentiment Rating of 0.14
www.americanbankingnews.com - April 26 at 5:58 PM
zacks.com logoCan the Rally in Mesoblast (MESO) Shares Continue?
www.zacks.com - April 24 at 2:56 PM
americanbankingnews.com logoMesoblast limited (MESO) Earning Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 11:17 PM
americanbankingnews.com logoMesoblast limited (MESO) Earning Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 17 at 3:54 PM
americanbankingnews.com logoMesoblast limited (MESO) Receives Media Impact Score of 0.44
www.americanbankingnews.com - April 14 at 2:48 PM
streetinsider.com logoForm 6-K MESOBLAST LTD For: Apr 13 - StreetInsider.com
www.streetinsider.com - April 14 at 8:43 AM
americanbankingnews.com logoMesoblast limited (MESO) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - April 11 at 5:53 PM
americanbankingnews.com logoMesoblast limited (MESO) Short Interest Update
www.americanbankingnews.com - April 11 at 7:13 AM
globenewswire.com logoMesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities - GlobeNewswire (press release)
globenewswire.com - April 7 at 11:09 AM
finance.yahoo.com logoMesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities
finance.yahoo.com - April 7 at 11:09 AM
americanbankingnews.com logoMesoblast limited (MESO) Stock Rating Reaffirmed by Scotiabank
www.americanbankingnews.com - April 3 at 7:34 PM
americanbankingnews.com logoMesoblast limited (MESO) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 1 at 2:15 PM
streetinsider.com logoMesoblast (MESO) Says Independent Data Monitoring Committee Initiates Process for Interim Analysis of Phase 3 Chronic Heart Failure Trial
www.streetinsider.com - March 31 at 6:36 PM
reuters.com logoBRIEF-IDMC starts interim analysis of Mesoblast's phase 3 heart failure trial
www.reuters.com - March 31 at 6:36 PM
americanbankingnews.com logoMaxim Group Reiterates Buy Rating for Mesoblast limited (MESO)
www.americanbankingnews.com - March 31 at 11:20 AM
globenewswire.com logoIndependent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast's Phase 3 Chronic Heart ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 9:41 AM
streetinsider.com logoMaxim Group Reiterates Buy Rating and $14 PT on Mesoblast Limited (MESO); 'Locking the Database Up for Interim ... - StreetInsider.com
www.streetinsider.com - March 31 at 9:41 AM
fool.com logoWhy the Mesoblast limited share price has been crushed today
www.fool.com.au - March 27 at 10:26 AM
americanbankingnews.com logoMaxim Group Reiterates Positive Rating for Mesoblast limited (MESO)
www.americanbankingnews.com - March 21 at 7:40 AM
us.rd.yahoo.com logoDurable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy
us.rd.yahoo.com - March 15 at 6:45 PM
fool.com logoWhy MesoBLAST limited is rocketing higher on FDA approval
www.fool.com.au - March 9 at 12:17 AM
reuters.com logoBRIEF-FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease
www.reuters.com - March 7 at 6:16 PM
us.rd.yahoo.com logo6:01 am Mesoblast announces that the FDA has granted a Fast Track designation for the use of its cell therapy, MSC-100-IV, to achieve improved overall response rate in children with steroid refractory acute Graft Versus Host Disease
us.rd.yahoo.com - March 7 at 6:16 PM
streetinsider.com logoMesoblast Limited (MESO) MSC-100-IV Granted Granted FDA Fast ... - StreetInsider.com
www.streetinsider.com - March 7 at 10:29 AM
nasdaq.com logoMesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December 3
www.nasdaq.com - February 26 at 5:41 PM
finance.yahoo.com logoMesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December 31, 2016
finance.yahoo.com - February 26 at 5:41 PM
finance.yahoo.com logoDurable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell Therapy in Rheumatoid Arthritis Patients Resistant to Anti-TNF Agents
finance.yahoo.com - February 16 at 6:06 PM
finance.yahoo.com logo4:56 pm Mesoblast announces 39-week date from its Phase 2 trial in patients with rheumatoid arthritis resistant to anti-Tumor Necrosis Factor agents
finance.yahoo.com - February 16 at 6:06 PM
finance.yahoo.com logoMesoblast Director Recognized by Peers for Cardiovascular Leadership
finance.yahoo.com - January 31 at 7:24 PM

Social

Chart

Mesoblast limited (MESO) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff